[Special Stock] Neocrema, Fear of Pediatric Mysterious Disease... Global Company Supplies Immunoglobulin Products

[Asia Economy Reporter Hyungsoo Park] NeoCrema's stock price is rising. The news that suspected cases of pediatric multisystem inflammatory syndrome, known as 'children's mysterious disease,' have been discovered in Korea appears to have influenced the stock price.

At 2:34 PM on the 26th, NeoCrema was trading at 8,510 KRW, up 6.91% from the previous day.

The Central Disease Control Headquarters announced that two suspected cases of pediatric multisystem inflammatory syndrome were reported on the same day. Both cases were reported by medical institutions in the Seoul area. The health authorities are currently conducting a detailed investigation into the two reported cases.

Since it was first reported in Europe last month, as of the 23rd, it has spread to 13 countries. It shows symptoms similar to Kawasaki disease, an acute febrile rash syndrome that usually occurs in children under 4 years old, and in severe cases, it is known to lead to death. The exact cause has not yet been identified. In the United States, cases have also been reported in adults in their 20s. Current treatment involves anti-inflammatory agents including immunoglobulin and steroids. Most cases improve, but there are rare instances of death.

Founded in 2007, NeoCrema specializes in producing functional food materials used in health functional foods such as prebiotics. Beyond simple production, it has research and development capabilities and has obtained certifications that meet international standards, establishing a global production system. NeoCrema develops and supplies global companies with products centered on the microbiome, including appetite suppressants, immune enhancers using immunoglobulin, and skin improvement agents.

NeoCrema particularly produces functional products that account for 83% of the microbiome market. The microbiome is a concept combining microbiota and genome, representing an industry that produces products through research on the functions of microorganisms within the human body.

If intestinal antibody microorganisms can be activated through the microbiome, fundamental treatment for bacterial and infectious diseases becomes possible, which raises expectations for market growth.

Globally, the development of microbiome-based therapeutics is still in its early stages. As various associations between the microbiome and diseases have been revealed, development of diverse therapeutics targeting cancer, autoimmune diseases, external organs, diabetes, obesity, and more is underway. BCC Research projected that the microbiome market will rapidly grow from $56 million in 2018 to $9.4 billion by 2024.

To respond to the global growth of clean label foods and the organic market, NeoCrema launched the world's first organic galactooligosaccharide. It is the world's number one manufacturer of organic galactooligosaccharide. The product is applied and sold to well-known domestic and overseas infant formula manufacturers. It is the world's first product to obtain Chinese organic certification (organic farming certification), targeting the Chinese and global markets.